H3 Biomedicine | GenomeWeb

H3 Biomedicine

The partnership marries Foundation's genomic knowledgebase with H3's drug discovery engine and computational biology platform.

NEW YORK (GenomeWeb News) – BGI and H3 Biomedicine today announced they will sequence and publish data from next-generation sequencing-based research on pre-clinical cancer models.

This article has been updated to clarify the tools being co-developed by H3 Biomedicine and Sage Bionetworks

NEW YORK (GenomeWeb News) – Cancer biotherapeutics developer H3 Biomedicine said today that it will partner with Sage Bionetworks to develop new software aimed at supporting its efforts to predict human responses to certain drugs.

NEW YORK (GenomeWeb News) – Horizon Discovery and H3 Biomedicine today launched SyntheTx, a technology partnership created to provide novel oncology targets and early-stage drug discovery programs to drug manufacturers.

NEW YORK (GenomeWeb News) – Horizon Discovery and biopharmaceutical firm H3 Biomedicine today announced a collaboration to identify and validate a panel of novel cancer drug targets.

Compendia Bioscience said this week that H3 Biomedicine has signed a three-year licensing agreement to use Compendia's Oncomine tool suite, which includes Oncomine Concepts and Oncomine Power Tools.

"H3 Biomedicine is an independent entity that will have the scientific freedom to choose and follow targets it identifies using genomic insights and modern chemistry, coupled with a disciplined approach to drug discovery and development," an Eisai spokesperson told PGx Reporter.

H3 Biomedicine will use a pharmacogenomic approach to develop new oncology drugs.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.